Global Stem Cells, Inc., Bioheart, Inc., and Paul Perito Urology Announce Plans to Launch Stem Cell Clinical Trials for Treatment of Erectile Dysfunction (ED)

Global Stem Cells Group and Bioheart, Inc. have announced the launch of a clinical trial for the treatment of erectile dysfunction (ED) using adipose-derived stem cell technology.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
stem cells,stem cell therapy,stem cell treatments,alternative medicine,stem cell medicine,cell therapy,adipose tissue,corpus cavernosum

Global Stem Cells Group

Cell therapy in this study will be composed of stem cells derived from a patient’s own adipose (fat) tissue, harvested by syringe liposuction.

Miami, FL (PRWEB) February 11, 2014

Global Stem Cells Group, Bioheart, Inc., and Paul Perito Urology announce plans to launch stem cell clinical trials for treatment of Erectile Dysfunction (ED).

Paul Perito, M.D. of Perito Urology in Coral Gables, Florida and the principal investigator of the trial study, titled, "An Open-label, Non-randomized, Single-center Study to Assess the Safety and Effects of Autologous Adipose-derived Stromal Cells Delivered into the Corpus Cavernosum in Patients with Erectile Dysfunction," aims to assess the safety and efficacy of stem cell implantation therapy in patients with ED.

The cell therapy in this study will be composed of stem cells derived from a patient’s own adipose (fat) tissue, harvested by syringe liposuction. The adipose stem cells will then be delivered into the corpus cavernosum of the penis.

Clinical trials will be held at Perito Urology, in cooperation with Global Stem Cells Group and Bioheart. Up to 20 patients will be enrolled.

Fort Myers Florida-based Emcyte Corporation, a leading provider of biotechnology products for platelet rich plasma and bone marrow concentrate grafting procedures, will be providing systems and kits to be used in the trial.

To learn more about Global Stem Cells Group's clinical trials, and for investor information, visit the Global Stem Cell Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cell Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

About Bioheart, Inc.:

Bioheart committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.

Bioheart’s goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

About Paul Perito, M.D.:

Paul Perito, M.D. is a top urological surgeon who excels in men’s sexual health and the treatment of erectile dysfunction (ED). Perito Urology is among the world’s top penile implant facilities. Completing more than 500 successful penile implant surgeries each year, Perito Urology offers a spectrum of services that include the treatment of Peyronie’s Disease and all other forms of urologic care related to erectile function and men’s health. The clinic is located near Miami, Florida in Coral Gables.

Perito is Chairman of Urology at Coral Gables Hospital and an active, Board Certified member of the American Urological Association. He is a Fellow of the American College of Surgeons, member of the Sexual Medicine Society and a member of the Society of Prosthetic Surgeons. Perito has established a penile implant training program for surgeons wishing to learn his minimally invasive technique. For more information on Perito and Perito Urology, visit his website PeritoUrology.com.

###


Contact

Attachments